Arrowpoint Advisory’s Healthcare team has advised Veramed, a specialist biostatistics and programming Contract Research Organisation (CRO) serving pharmaceutical and biotech clients across the UK, Europe and US on its partnership with Livingbridge.
Founded in 2012 by Matthew and Emma Jones and headquartered in London, Veramed provides statistical consulting, programming and study reporting, and market launch and commercialisation services to clients globally. The business has since scaled both nationally and internationally through establishing offices in multiple locations across the UK and international offices in mainland Europe, the Ukraine and the US. Alongside this, investments in new services and continuing to build a high performing team with a collaborative culture have led to the business realising market-leading-organic
The investment has been made through Livingbridge’s Enterprise 3 fund, which invests in fast growth SMEs.
The Company’s founders Matthew and Emma Jones will retain a significant shareholding and along with the existing management team continue to manage the business on a day-to-day basis. Livingbridge’s investment will support the Company’s strategy to expand geographically, broaden its offering and continually improve its employee and client experience.
Matthew Jones, Co-Founder and Chief Executive Officer of Veramed, says: “We are excited to be announcing our partnership with Livingbridge, a partner that shares our values and has the capability to help us expand our capacity and reach within the pharma services sector.”
Emma Jones, Co-Founder & Executive Vice President, Statistics at Veramed, adds: “The support and practical advice that Karen and the rest of the team at Arrowpoint Advisory provided from start to finish was invaluable. They fully understood the importance of finding the right partner for the business and carefully crafted a process around that – we are delighted with the outcome.”
Karen Dawaf Harron, Director at Arrowpoint Advisory, says: “It has been an absolute pleasure to work with the Veramed team. Matt and Emma have built an exceptional brand synonymous with quality and integrity. The highly specialist nature of work that Veramed undertakes means it’s uniquely positioned to gain market share domestically and internationally. We are delighted to have supported Veramed on this milestone transaction. We believe that the business will continue to go from strength to strength with the support of an experienced investor.”